5305-45-3

Usage

Uses

Used in Organic Synthesis:
4,6-dichloropyrimidine-5-carbonitrile is used as an organic synthesis intermediate for the preparation of a wide range of chemical compounds. Its reactivity and functional groups make it a valuable building block in the synthesis of various organic molecules, including those with potential applications in materials science, agrochemicals, and specialty chemicals.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 4,6-dichloropyrimidine-5-carbonitrile is employed as a key intermediate in the development of new drugs. Its unique chemical structure allows for the creation of novel drug candidates with potential therapeutic applications. 4,6-dichloropyrimidine-5-carbonitrile can be further modified and functionalized to produce a variety of pharmaceutically relevant molecules, contributing to the advancement of drug discovery and development.
Used in Laboratory Research and Development:
4,6-dichloropyrimidine-5-carbonitrile is also utilized in laboratory research and development processes. It serves as a valuable tool for chemists and researchers working on the synthesis and characterization of new organic and pharmaceutical compounds. 4,6-dichloropyrimidine-5-carbonitrile's reactivity and structural features make it an essential component in the design and synthesis of novel molecules with potential applications in various fields.
Used in Chemical Production Process:
In the chemical production process, 4,6-dichloropyrimidine-5-carbonitrile plays a significant role as an intermediate in the large-scale synthesis of various chemicals and pharmaceuticals. Its versatility and reactivity enable the efficient production of a wide range of compounds, contributing to the overall efficiency and cost-effectiveness of the chemical manufacturing process.

Synthesis

4,6-Dichloro-5-pyrimidinecarbaldehyde oxime (8 g) was dissolved in CHCl3 (40 mL) and treated with SOCl2 (6 mL) for 2 h at rt. The solvent was removed and the residue was dissolved in DCM (5 mL). The resulting solid was filtered and washed with DCM (5 mL). The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography using DCM-hexane (3:1) to give 4,6-dichloro-5-pyrimidinecarbonitrile. White solid.

InChI:InChI=1/C5HCl2N3/c6-4-3(1-8)5(7)10-2-9-4/h2H

Upstream product

• 1277179-40-4 4, 6-dichloropyrimidine-5-carbaldehyde oxime 
• 5305-40-8 2,6-dichloro-pyrimidine carbaldehyde 
• 15263-75-9 N-((4,6-dihydroxypyrimidin-5-yl)methylene)-N-methylmethylammonium chloride salt 
• 5305-43-1 C₅H₂ClN₃O 
• 911461-47-7 iminohydroxy intermediate 
• 7660-48-2 4,6-dichloropyrimidine-5-carbaldehyde oxime 

Downstream Products

• 425394-86-1 4-chloro-5-cyano-6-methoxypyrimidine 
• 914308-84-2 4-chloro-6-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrimidine-5-carbonitrile 
• 944342-92-1 4-(4-benzyloxy-3-chloro-phenylamino)-6-chloro-pyrimidine-5-carbonitrile 
• 733748-89-5 4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methanesulfonyl-phenoxy)-pyrimidine-5-carbonitrile 
• 60025-09-4 4-amino-6-chloropyrimidine-5-carbonitrile 
• 914310-34-2 5-(3-chloro-4-fluoro-phenyl)-3H,5H-1-thia-3,5,6,8-tetraaza-acenaphthylen-4-one 
• 914308-09-1 [6-(3-chloro-4-fluoro-phenylamino)-5-cyano-pyrimidin-4-ylsulfanyl]-acetic acid 
• 914310-37-5 5-(3-chloro-4-fluoro-phenyl)-2-nitro-3H,5H-1-thia-3,5,6,8-tetraaza-acenaphthylen-4-one 
• 914308-85-3 {5-cyano-6-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrimidin-4-ylsulfanyl}-acetic acidethyl ester 
• 1605327-10-3 (S)-4-amino-6-((1-(5-((2-((2-(dimethylamino)ethyl)amino)phenyl)thio)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile 
• 1605329-28-9 (S)-4-amino-6-((1-(5-((3-fluoro-4-methoxyphenyl)thio)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile 
• 1605329-19-8 (S)-4-amino-6-((1-(5-((3-methoxyphenyl)thio)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile 
• 1605326-60-0 (S)-4-amino-6-((1-(5-((2-hydroxyphenyl)thio)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl)amino)-pyrimidine-5-carbonitrile 

Relevant academic research and scientific papers

An Alternative Scalable Process for the Synthesis of 4,6-Dichloropyrimidine-5-carbonitrile

A robust, safe, and scalable process for the synthesis of 4,6-dichloropyrimidine-5-carbonitrile is described. All of the intermediates in the process are storable under normal conditions. Significant process safety evaluation was undertaken in this route, and the highlights of these studies are presented. This scalable and safe synthetic strategy can be applied for multikilogram-scale production.

Method for synthesizing 4,6-dichloropyrimidine-5-carbonitrile

The invention relates to a method for synthesizing a compound 4,6-dichloropyrimidine-5-carbonitrile. The method has the advantages of mild reaction conditions, environmental protection, easiness in preservation of an intermediate, and convenience for large-scale production.

QUINOLINE DERIVATIVES AS PIK3 INHIBITORS

Substituted bicyclic heteroaryls having the general formula (I) and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pl 108 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML), Myelodysplastic syndrome (MDS), myeio-proiiferative diseases (MPD), Chronic Myeloid Leukemia (CML), T-cell Acute Lymphoblastic leukaemia (T-ALL), B-cell Acute Lymphoblastic leukaemia (B-ALL), Non Hodgkins Lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.

Synthesis and SAR development of novel mGluR1 antagonists for the treatment of chronic pain

High throughput screening identified the pyridothienopyrimidinone 1 as a ligand for the metabotropic glutamate receptor 1 (mGluR1 = 10 nM). Compound 1 has an excellent in vivo profile; however, it displays unfavorable pharmacokinetic issues and metabolic

Synthesis of Janus type nucleoside analogues and their preliminary bioactivity

Novel Janus type nucleoside analogues 1a and 1b were synthesized in seven steps from 2-amino-4,6-dihydroxypyrimidine and 4,6-dihydroxypyrimidine. The base moiety of 1a has one face with a Watson-Crick donor-donor-acceptor (DDA) H-bond array of guanine and

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Fused tricyclic mGIuR1 antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGlu

SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS

The present invention is directed to thienopyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.